Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fundraising Cognitive Disorder Videogame Maker Akili Has Big Pharma Buy-In

This article was originally published in Scrip

Executive Summary

What if a video game could treat a player's cognitive disorder? It may sound like a sci-fi fantasy, but a company developing such a platform has secured the backing of Shire and Jazz Venture Partners, entered into a partnership with Pfizer and has recently raised $30.5m in equity investments.

You may also be interested in...

Merck, Amgen Invest In Medical Video Game Developer Akili

Akili Interactive Labs Inc., a digital medicine company, has secured an additional $11.9m funding via series B financing with backing from Merck KGaA and Amgen Inc.

Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?

How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.

Adherence Issues Add Weight To Digital Trials Push

Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts